Renovaro (RENB) Competitors $0.18 +0.01 (+8.23%) Closing price 04:00 PM EasternExtended Trading$0.18 +0.00 (+1.71%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RENB vs. IVVD, ZURA, ONCY, FBRX, GNLX, PLX, ADAG, CGEN, SKYE, and IKTShould you be buying Renovaro stock or one of its competitors? The main competitors of Renovaro include Invivyd (IVVD), Zura Bio (ZURA), Oncolytics Biotech (ONCY), Forte Biosciences (FBRX), Genelux (GNLX), Protalix BioTherapeutics (PLX), Adagene (ADAG), Compugen (CGEN), Skye Bioscience (SKYE), and Inhibikase Therapeutics (IKT). These companies are all part of the "pharmaceutical products" industry. Renovaro vs. Its Competitors Invivyd Zura Bio Oncolytics Biotech Forte Biosciences Genelux Protalix BioTherapeutics Adagene Compugen Skye Bioscience Inhibikase Therapeutics Renovaro (NASDAQ:RENB) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Is RENB or IVVD more profitable? Renovaro has a net margin of 0.00% compared to Invivyd's net margin of -238.33%. Renovaro's return on equity of -60.38% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets RenovaroN/A -60.38% -47.04% Invivyd -238.33%-177.89%-90.96% Do insiders & institutionals hold more shares of RENB or IVVD? 71.4% of Renovaro shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 0.5% of Renovaro shares are held by company insiders. Comparatively, 25.4% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher valuation & earnings, RENB or IVVD? Renovaro has higher earnings, but lower revenue than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovaroN/AN/A-$88.43M-$0.77-0.23Invivyd$25.38M5.78-$169.93M-$0.92-1.33 Does the media refer more to RENB or IVVD? In the previous week, Invivyd had 3 more articles in the media than Renovaro. MarketBeat recorded 3 mentions for Invivyd and 0 mentions for Renovaro. Invivyd's average media sentiment score of 0.65 beat Renovaro's score of 0.00 indicating that Invivyd is being referred to more favorably in the news media. Company Overall Sentiment Renovaro Neutral Invivyd Positive Do analysts recommend RENB or IVVD? Invivyd has a consensus price target of $3.18, suggesting a potential upside of 160.93%. Given Invivyd's stronger consensus rating and higher possible upside, analysts plainly believe Invivyd is more favorable than Renovaro.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Renovaro 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more risk & volatility, RENB or IVVD? Renovaro has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. SummaryInvivyd beats Renovaro on 9 of the 16 factors compared between the two stocks. Get Renovaro News Delivered to You Automatically Sign up to receive the latest news and ratings for RENB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RENB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENB vs. The Competition Export to ExcelMetricRenovaroMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.83M$3.16B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-0.2320.5276.4826.75Price / SalesN/A446.54531.95124.23Price / CashN/A46.0037.9261.55Price / Book0.209.6613.726.40Net Income-$88.43M-$53.02M$3.29B$271.62M7 Day Performance-11.93%1.09%1.03%2.85%1 Month Performance-25.25%7.93%6.32%9.64%1 Year Performance-67.41%10.48%81.16%31.62% Renovaro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENBRenovaro0.4625 of 5 stars$0.18+8.2%N/A-70.1%$27.83MN/A-0.2320Gap UpHigh Trading VolumeIVVDInvivyd3.4472 of 5 stars$1.16-0.4%$3.18+175.6%+6.8%$138.76M$25.38M-1.26100ZURAZura Bio3.5927 of 5 stars$2.12-4.0%$14.00+559.8%-50.4%$137.91MN/A-3.033Short Interest ↓ONCYOncolytics Biotech2.3063 of 5 stars$1.38+7.4%$5.00+263.6%+46.2%$137.90MN/A-5.0930News CoverageAnalyst RevisionGap UpHigh Trading VolumeFBRXForte Biosciences3.1307 of 5 stars$10.90-2.1%$68.00+523.9%+96.3%$135.49MN/A-0.675Options VolumeGap UpGNLXGenelux0.9754 of 5 stars$3.61+1.4%$20.33+463.4%+63.7%$135.41M$10K-4.1710PLXProtalix BioTherapeutics1.8957 of 5 stars$1.67+5.4%$15.00+800.9%+70.6%$132.67M$61.95M-12.80200Positive NewsADAGAdagene3.0898 of 5 stars$2.76+15.5%$7.00+153.6%-2.4%$130.08M$100K0.00260News CoverageHigh Trading VolumeCGENCompugen1.0638 of 5 stars$1.43-1.7%$4.00+180.7%-29.5%$127.17M$27.86M-6.4870Positive NewsSKYESkye Bioscience1.6713 of 5 stars$3.97-3.6%$15.50+290.4%-24.8%$122.69MN/A-3.7311Gap UpIKTInhibikase Therapeutics1.2819 of 5 stars$1.65-0.9%$6.50+295.1%+31.6%$122.58MN/A-0.626 Related Companies and Tools Related Companies Invivyd Alternatives Zura Bio Alternatives Oncolytics Biotech Alternatives Forte Biosciences Alternatives Genelux Alternatives Protalix BioTherapeutics Alternatives Adagene Alternatives Compugen Alternatives Skye Bioscience Alternatives Inhibikase Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RENB) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RENB Stock Alerts